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Abstract
Objective: The purpose of this study was to investigate the effect of acute and chronic whole-body vibration
exercise on serum insulin-like growth factor-1 (IGF-1) levels in women with fibromyalgia.
Methods: A randomized controlled two-factor mixed experimental design was used. Twenty-four women with
fibromyalgia (age standard error of the mean, 54.95 2.03) were randomized into the vibration group or the
control group. The vibration group underwent a protocol of static and dynamic tasks with whole-body vibration
exercise twice a week for a total of six weeks, whereas the control group performed the same protocol without
vibratory stimulus. Both groups continued their usual pharmacological treatment. Serum IGF-1 levels were
determined using enzyme-linked immunosorbent assay (ELISA). To test the effects of long-term whole-body
vibration exercise, serum IGF-1 measurements were taken at baseline and at weeks 1, 3, and 6 of the intervention.
To test the short-term effects, at week 1, serum IGF-1 measurements were taken before and immediately following
a session of whole-body vibration exercise.
Results: Treatment adherence was 93% in the vibration group and 92% in the control group. None of the subjects
dropped out of the study. There was an absence of change in IGF-1 at week 1 and week 6 of whole-body
vibration exercise.
Conclusion: Results show no change in serum IGF-1 levels in women with fibromyalgia undergoing whole-body
vibration exercise. Although high-intensity exercise and whole-body vibration exercise have been shown to
increase serum IGF-1 in healthy individuals, the effectiveness of whole-body vibration exercise as a strategy to
produce improvements in serum IGF-1 levels in women with fibromyalgia could not be demonstrated.
Introduction
Fibromyalgia (FM) syndrome is a chronic rheumaticcondition of unknown etiology characterized by wide-
spread noninflammatory musculoskeletal pain with tender-
ness on palpation in a minimum of 11 of the 18 tender points
for at least 3 months.1 Numerous symptoms may also be
associated with this syndrome, including fatigue, anxiety,
depression, nonrestorative sleep, muscular stiffness, and ir-
ritable bowel syndrome. The management of FM is based on
a symptomatic multidisciplinary treatment through pharma-
cologic and nonpharmacologic strategies. Among all non-
pharmacologic treatments, exercise has the strongest evidence
of efficacy.2
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Whole-body vibration (WBV) is a mode of exercise that
has been used to improve muscle strength, bone density, and
balance in healthy adults3 and aging populations.4,5 In this
therapy, the subject stands on a platform that generates
sinusoidal vertical vibrations, while performing different
exercises with a frequency and amplitude ranging from 20 to
50Hz and 2.0 to 10.5mm, respectively. Previously, we
demonstrated significant improvements in pain and fatigue
following a WBV intervention in patients with FM.6 Also,
WBV has been shown to induce increases in serotonin, 5-
hydroxyindoleacetic acid, and growth hormone (GH).7–10
The effects on GH have been attributed to a muscle afferent–
pituitary axis.8,11–12 GH is a 191-amino-acid polypeptide
hormone synthesized and secreted in a pulsatile manner by
the anterior pituitary gland. Serum insulin-like growth fac-
tor-1 (IGF-1) is secreted mainly by the liver in response to
GH release.13 Although some authors have failed to demon-
strate changes in serum hormone levels in non-FM patitents
following WBV,8,14 Cardinale et al. recently demonstrated a
significant increase in serum IGF-1 following a single expo-
sure to WBV in elderly patients.15
An impairment of the hypothalamic–pituitary–GH–IGF-1
axis has been postulated as one among several mechanisms
implicated in the pathophysiology of FM.16–18 This impair-
ment is manifested by a reduction in serum IGF-1 levels,17–21
which in turn has been related to sleep disturbances, poor
muscle performance, fatigue, and muscle pain.17 Indeed, GH
therapy has shown improvements in symptoms and daily
functioning in women with FM,22 but the high cost of this
therapy prevents extended use. Therefore, investigating the
effectiveness of a low cost physiologic strategy—WBV—to
increase IGF-1 levels in women with FM seems appropriate.
The application of acute and chronic WBV in women with FM
has been neglected.
The purpose of this study was to investigate the effect of
acute and chronic WBV on serum IGF-1 levels in women
with FM. It was hypothesized that women with FM would
exhibit an increase in IGF-1.
Patients and Methods
Subjects
Participants were recruited by referral from family physi-
cians and through public announcements distributed in local
FM associations in Barcelona, Spain. Ninety-two (92) women
expressed interest in the study, and those who met the
American College of Rheumatology criteria for FM for at least
three years were considered for the study.1 Of 92 women, 24
were recruited for this study (Table 1). None of the partici-
pants had a medical history of liver disease that could alter
IGF-1 levels (Table 2). Women were excluded if they had any
orthopedic limitation; a cardiovascular, pulmonary, or meta-
bolic disease that would preclude exercise; or were partici-
pating in any other study (Fig. 1). Written informed consent
was obtained from each subject prior to participation in the
study according to procedures approved by theCommittee on
Biomedical Ethics of the Jordi Gol Gurina Foundation (Spain).
Study design
To investigate the effect of WBV, a two-factor (group
time) mixed experimental design was employed in this study.
Women were randomized into two treatment groups: vibra-
tion (VG) and control (CG). To test the effect of long-term
(chronic) WBV, serum IGF-1 measurements were taken at
baseline and at weeks 1, 3, and 6 of intervention. To test the
effect of short-term (acute) WBV, at week 1, serum IGF-1
measurements were taken before and immediately following
a session of WBV. Prior to the start of the study, an individ-
ualized interview with each patient obtained the following
information: 1) complete medical history, 2) current medi-
cations, 3) physical activity habits, and 4) preferred types of
exercises. Six subjects reported participating in 30 minutes of
cardiovascular exercise at least three times per week, meeting
the American College of Sports Medicine exercise recom-
mendations.23 Active subjects were distributed equally be-
tween the two groups. Medication and physical activity
regimens were monitored throughout the study. Participants
were instructed to report any changes in both aspects. Addi-
tionally, an individualized weekly medical interview was
conducted in order to monitor FM-related symptoms.
Treatment groups
The VG underwent a protocol with WBV twice a week for
a total of six weeks, whereas the CG performed the same pro-
tocol without vibratory stimulus. For the CG, the vibratory
Table 1. Demographic Characteristics
Vibration group
(n¼ 12)
Control group
(n¼ 12)
Age, years 55.75 3.09 54.17 2.74
Height, cm 156.25 2.05 156.92 1.88
Weight, kg 67.92 2.8 70.41 3.1
BMI, kg=m2 27.26 0.41 28.15 1.12
Duration of
diagnosis, years
9.58 0.59 9.66 0.48
Baseline FIQ scores 63.5 3.57 67.88 2.33
Shown as mean standard error of the mean.
BMI, body–mass index; FIQ, Fibromyalgia Impact Questionnaire.
Table 2. Comorbidities and Medications
Vibration group
(n¼ 12)
Control group
(n¼ 12)
Comorbidity
Gonarthrosis 7 (58.3%) 6 (49.8%)
Spondyloarthrosis 8 (66.6%) 7 (58.3%)
Disc degeneration 4 (33.3%) 2 (16.6%)
Coxarthrosis 1 (8.3%) 1 (8.3%)
Osteoporosis 2 (16.6%) 1 (8.3%)
Cardiopathy 1 (8.3%) 0
Depression 6 (49.8%) 5 (41.6%)
Hypertension 2 (16.6%) 2 (16.7%)
Circulatory disease 1 (8.3%) 1 (8.3%)
Carpal tunnel 2 (16.6%) 2 (16.7%)
Irritable bowel 1 (8.3%) 0
Medication
Antidepressants 7 (58.3%) 5 (41.6%)
Anxiolytics 6 (49.8%) 4 (33.3%)
NSAIDs 4 (33.3%) 4 (33.3%)
Analgesics 4 (33.3%) 3 (25.0%)
Muscle relaxants 1 (8.3%) 2 (16.7%)
NSAIDs, non-steroidal anti-inflammatory drugs.
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apparatus was turned on yet did not produce vibrations, a
strategy that has been used previously by others.8,15,24 We
informed both groups that they would receive two different
types of vibratory stimulus, one perceptible and one imper-
ceptible (ultrasound-like), thus maintaining the potential of a
placebo effect in both groups.15 Both groups were instructed
to continue with their pharmacological care, which was
standardized and recommended for these patients.2 All ex-
ercise sessions were conducted by the same instructor, who
had experience in working with FM. The protocol with WBV
was supervised by experienced investigators. The two per
week frequency of sessions was adopted to avoid the risk of
exacerbating symptoms and ensure adherence.
Exercise protocol
The protocol consisted of performing static and dynamic
tasks while standing on a WBV platform (PowerPlate, Bad-
hoevendorp, The Netherlands). The tasks were: a) static squat
at 1008 of knee flexion; b) dynamic squat between 908 and 1308
of knee flexion; c) maintained ankle plantar flexion with legs
in extension; d) flexo-extension of the right leg between 1008
and 1308 of knee flexion; e) flexo-extension of the left leg be-
tween 1008 and 1308 of knee flexion; f ) squat at 1008 of knee
flexion, shifting the body weight from one leg to the other.
For all tasks, subjects held onto the supporting bar. The six
exercises (30 seconds each) were repeated six times with a
recovery time of 3minutes in between. To facilitate an optimal
training progression, workload was reduced during the first
two sessions, with subjects only performing three (exercises a,
b, and c; each repeated three times) of the six exercises.
Whole-body vibration
The WBV intensity was kept constant at 30Hz frequency
and 2mmamplitude (low amplitude); whereas for the CG, the
apparatus did not produce vibrations. The intensity of
vibration was chosen based on the literature.3,6,25 Thirty Hz
has been shown to induce the maximal muscular electrical
activity. Lower frequencies (20Hz) were not used because
they evoke muscular relaxation, whereas higher frequencies
(50Hz) and amplitudes were not employed because they can
generate severe soreness in untrained individuals.3,25 The
duration of WBV was 4.5 minutes per session for the first two
sessions, and 18 minutes for the remaining ten sessions. Thus,
the total duration after completion of 6 weeks (12 sessions)
was 189 minutes.
Blood collection and hormonal analysis
Blood samples were obtained non-fasting from the ante-
cubital vein. To minimize diurnal hormonal variations, all
samples were collected by the same experienced nurses at the
same time of day (between 9:00 am and 11:00 am). The blood
samples were allowed to clot, centrifuged at 3000 rpm for 10
minutes, and the serum was stored at 708C. Serum IGF-1
concentration was determined by enzyme-linked immuno-
sorbent assay (ELISA) (R&D Systems, Minneapolis, MN).
Prior to assay, each sample was acid-alcohol extracted to
minimize IGF-1 binding protein interference.26 The intra-
assay coefficient of variance was 8.32%.
Statistical analysis
Descriptive statistics were used to summarize the demo-
graphic characteristics of the subjects and independent t-test
was used to compare the demographic variables between the
VG and CG. To test the effect of WBV on IGF-1 at week 1 and
at week 6, a 22 and 24 (grouptime) mixed design
repeated measures ANOVAwas performed, respectively. All
data are presented as mean standard error of the mean
FIG. 1. Study design. IGF-1,
insulin-like growth factor-1.
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(SEM). For all statistical tests, the alpha level was set at 0.05.
Statistical analyses were performed with SPSS v.15.0.
Results
There were no differences (p> 0.05) between the groups
for any demographic variables. Both the VG and CG adhered
to the treatments 93% and 92%, respectively. None of the sub-
jects dropped out of the study. All participants reportedmain-
taining their prescribed medications throughout the study.
This program did not exacerbate FM-related symptoms
nor did it result in musculoskeletal injuries. However, one
patient exhibited a mild anxiety attack on the first session
of WBV. This patient responded normally for the remain-
ing of the sessions. Fig. 2 illustrates the absence of change
in IGF-1 following acute (F(1,22)¼ 0.40; p¼ 0.532) and chronic
(F(1,3)¼ 0.51; p¼ 0.674) WBV.
Discussion
Patients with FM exhibit low levels of serum IGF-1,17–21
which has been related to symptoms of FM.17 In fact, daily
injections of GH improve symptoms of FM.22 In the present
investigation, we assessed the effectiveness of a non-
pharmacologic strategy to increase IGF-1 levels in patients
with FM. Contrary to our hypothesis, acute and chronic WBV
did not elicit a change in serum IGF-1.
The characteristics of participants in this intervention were
similar to these of other studies in terms of comorbidities,
medications, and demographics. Although we expected sig-
nificant results, the absence of change in IGF-1 following
WBV in our study can be supported by other investiga-
tors.8,14,27 Cardinale and colleagues assessed acute responses
of testosterone and IGF-1 levels following a session of WBV
in healthy young individuals.8 The protocol consisted of 20
minutes (2 sets of 10 minutes each with a recovery time of 5
minutes between sets) of WBV with a frequency of 30Hz and
peak-to-peak amplitudes of 1.5mm and 3mm. Each set
consisted of 10 repetitions of static half squat for 1 minute
with a recovery time of 1 minute. No changes in testosterone
and IGF-1 were found at 10 minutes of WBV, immediately
after the WBV, or 24 hours after the session. Di Loreto et al.
similarly assessed the responses of testosterone and IGF-1
levels following a session of WBV in healthy men.14 The
protocol consisted of 10 minutes of WBV with a frequency of
30Hz and peak-to-peak amplitude of 4mm. No changes in
testosterone and IGF-1 were found up to 1 hour following
the session of WBV. The consistency of findings between our
study and those of Cardinale8 and Di Loreto14 could be at-
tributed to similarities in duration, frequency, and amplitude
in WBV among these studies. In contrast, in a recent study,
Cardinale et al. demonstrated a significant increase in serum
IGF-1 levels after an acute exposure of 5 minutes to WBV in
elderly patients without FM.15 The protocol consisted of 5
repetitions of static half squat of 1 minute each, with a 1
minute recovery time, at a frequency of 30Hz and a peak-
to-peak amplitude of 4mm. Participants undergoing WBV
showed a significant increase in serum IGF-1 immediately
after finishing the WBV session compared to the control
group. Improvements were maintained up to 2 hours after
the vibration stimulus. The discrepancy in results between
our study and that of Cardinale et al.15 could be attributed
to different subject populations (we use FM patients) or
differences in exercise=recovery time ratio (frequency and
amplitude of vibration were similar).15
There are no studies evaluating the effect of long-termWBV
on IGF-1 in FM or in any other population. Jones et al. in-
vestigated the effect of 6 months of exercise on serum IGF-1 in
patients with FM.27 The intervention consisted of 60 minutes,
3 times per week, and included aerobic exercise, strength,
flexibility, balance training, and relaxation. No change in IGF-
1 was found following the 6-month exercise intervention.
Therefore, patients with FM do not exhibit any change in
serum IGF-1 levels following exposure to WBV for 6 weeks
or exposure to traditional exercise for 6 months.27
The lack of effect of WBV on serum IGF-1 levels in patients
with FM could be explained by an increased somatostatin
tone (an inhibiting factor for GH release) or an insufficient
WBV stimulus.27–29 The intensity-dependent speculation is
supported by evidence that moderate-intensity exercise does
not change IGF-1 levels,30,31 whereas strenuous exercise
does.32 During all forms of exercise, acute endocrine activa-
tion is triggered by collaterals of the central motor command
to the hypothalamic neurosecretory and autonomic centers.8
The intensity required for these hormone-induced responses
to occur seems to be high.32 Patients with FM may be unable
to exercise at a high enough intensity to stimulate IGF-1 se-
cretion without exacerbating FM-related symptoms.27 Thus,
the use of WBV=exercise as a strategy to induce improve-
ments in serum IGF-1 levels may be unrealistic. However,
recent findings15 justify the need for future research to de-
termine if a higher intensity WBV protocol can be safely ap-
plied to patients with FM to increase their serum IGF-1 levels.
There are some limitations to this study. First, to investigate
the acute effect of WBV on serum IGF-1, the use of a fully
FIG. 2. Serum insulin-like growth factor-1 (IGF-1) levels
during acute (A) and chronic (B) in both the whole-body
vibration (WBV) and control groups.
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repeated measures design (subjects serving as their own
controls) may appear more appropriate than the mixed re-
peated measures design; however, we are confident that a
change in the design would not have altered the findings of
the study. Second, no other biomarkers (GH-releasing hor-
mone, GH, or somatostatin) were measured, thus impeding
potential explanations for the lack of IGF-1 response. Future
research should explore the presence of an interaction be-
tween somatostatin and IGF-1 following WBV=exercise.
Third, given that no specific muscle IGF-1 isoforms (mechano
growth factor, or IGF-IEb) were measured,33 we cannot ex-
clude the potential effect of WBV on other IGF-1 markers. We
chose to assess serum IGF-1 to be consistent with the litera-
ture.8,14,15,17–21,27,30–32
Conclusions
In conclusion, our results suggest no changes in serum
IGF-1 following 1 week or 6 weeks of WBV in women with
FM. These findings are in agreement with most of the liter-
ature regarding healthy subjects. Although high-intensity
exercise and WBV have been shown to increase serum IGF-1
in healthy individuals, the effectiveness of WBV as a strategy
to produce improvements in serum IGF-1 levels in women
with FM remains questionable at this time. Future research
should focus on characterizing the WBV=IGF-1 dose re-
sponse in patients with FM; elucidating the mechanism for
this apparent blunted response in FM patients; and provid-
ing recommendations on effective and safe WBV protocols
for patients with FM.
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